

cobas® Liat® PCR System

Fast Facts



Product description

- CLIA-waived, lab-quality testing for Influenza A/B, Strep A, and Influenza A/B & RSV at the point of care
- Real-time RT-PCR/PCR technology is the recognized gold standard in molecular testing
- Accurate, actionable results with **no need for interpretation or confirmation of negative results**
- 3 easy steps with 1 minute of hands-on time and results in 20 minutes or less

cobas® Liat® Analyzer							
	cobas® Liat® Influenza A	cobas® Liat® Influenza B	cobas® Liat® Strep	cobas® Liat® Influenza A/B & RSV			
					Influenza A	Influenza B	RSV
Sensitivity	100%	100%	98.30%	Positive Agreement	98.40%	97.90%	97.80%
Specificity	96.80%	94.30%	94.2%	Negative Agreement	96.50%	99.40%	98.40%
Time to results	20 minutes		15 minutes	Time to results	20 minutes		
CLIA waived	Yes		Yes	CLIA waived	Yes		
Sample source	Nasopharyngeal swab		Throat Swab	Sample source	Nasopharyngeal Swab		

Data reflected in above table per cobas Liat Package Inserts

The **cobas® Liat® Strep A** assay demonstrated equivalent sensitivity (97.7%) and specificity (93.3%) to reference culture with a 15-minute turnaround time. In comparison to RADTs, the cobas Liat Strep A assay showed improved sensitivity (97.7% Liat vs 84.5% RADT)¹

Target market segments

- Pediatrics
- General physician's office
- Urgent Care/Clinics
- Hospitals

Who to target

- Customers currently using rapid antigen tests and/or rapid antigen readers
- Customers that currently require confirmation cultures for negative patient results and/or pediatric clinics who confirm negative results by culture
- Customers that do not have a fast and reliable testing mechanism during flu season

Qualifying questions

- What are you currently using to test for flu/strep/RSV?
- Are you familiar with molecular testing options and how they are different?
- What initiatives does your office currently have in place to minimize drug-resistant infections from overuse of antibiotics?
- Do prescribers tend to prescribe “just in case” or hold off until results are confirmed?
How does this impact patients and caregivers?
- Describe your current workflow for patient testing and resulting.

Product Description	Roche Catalog #
cobas® Liat® Analyzer	07341920190
cobas® Liat® Influenza A/B Kit (20 ct)	07341890190
cobas® Liat® Influenza A/B QC Kit	07402660190
cobas® Liat® Strep A Kit (20 ct)	07341911190
cobas® Liat® Strep A QC Kit	07402678190
cobas® Liat® Influenza A/B & RSV Kit (20ct)	08160104190
cobas® Liat® Influenza A/B & RSV QC Kit	07402686190
cobas® Liat® Cleaning Tool	07402759190

The following CPT® codes may describe tests run on the cobas® Liat® PCR System

CPT® code	Description	2017 Medicare NLA ²
87502	Infectious agent detection by nucleic acid (DNA or RNA); influenza virus for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, first 2 types or sub-types	\$116.73
87631	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets	\$175.98
87651	Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A , amplified probe technique	\$48.14

This information is provided as a courtesy for informational purposes only and is not intended to be, and should not be interpreted as, reimbursement or billing advice.

For more information about specific programs, promotions, and reagent/analyzer volume guidelines, please consult your Roche representative.

1 Wang, Fangnian et al. (2017) “Accurate detection of Streptococcus pyogenes at the point of care using the cobas Liat Strep A nucleic acid test,” *Clinical Pediatrics* 1:9922816684602. Accepted on Dec 2016.

2 Medicare payment rates may differ based on the geographic location where the test is performed but the rates cannot be higher than the Medicare National Limitation Amount (NLA). Medicaid rates may not be higher than the Medicare rates. Other nonMedicare (e.g., private payer) rates will vary.

Current Procedural Terminology (CPT®) copyright 2016 American Medical Association. All Rights Reserved. CPT® is a registered trademark of the American Medical Association.

COBAS and LIAT are trademarks of Roche. ©2017 Roche. PP-US-11171-0817